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ABSTRACT
We present a theory of pluralistic and stochastic
gene regulation. To bridge the gap between empir-
ical studies and mathematical models, we integrate
pre-existing observations with our meta-analyses of
the ENCODE ChIP-Seq experiments. Earlier evidence
includes fluctuations in levels, location, activity, and
binding of transcription factors, variable DNA motifs,
and bursts in gene expression. Stochastic regula-
tion is also indicated by frequently subdued effects
of knockout mutants of regulators, their evolution-
ary losses/gains and massive rewiring of regulatory
sites. We report wide-spread pluralistic regulation in
≈800 000 tightly co-expressed pairs of diverse hu-
man genes. Typically, half of ≈50 observed regula-
tors bind to both genes reproducibly, twice more than
in independently expressed gene pairs. We also ex-
amine the largest set of co-expressed genes, which
code for cytoplasmic ribosomal proteins. Numerous
regulatory complexes are highly significant enriched
in ribosomal genes compared to highly expressed
non-ribosomal genes. We could not find any DNA-
associated, strict sense master regulator. Despite
major fluctuations in transcription factor binding, our
machine learning model accurately predicted tran-
script levels using binding sites of 20+ regulators.
Our pluralistic and stochastic theory is consistent
with partially random binding patterns, redundancy,
stochastic regulator binding, burst-like expression,
degeneracy of binding motifs and massive regula-
tory rewiring during evolution.
INTRODUCTION
Most disease-associated mutations are located outside of
protein coding regions, likely affecting transcriptional reg-
ulation or chromosomal organization (1,2). To draw objec-
tive and consistent biological and clinical conclusions from
the over two million human genomes to be sequenced by
2020 (3), we need new models and theories of gene regula-
tion that are highly consistent with observations and mini-
mally biased (4). Almost inherent biases include the number
and selection of transcriptional regulators (TRs), knockout
mutants, amplification and sequencing bias. However, we
can avoid biased interpretation. Struggling with vast com-
plexity, human perception is naturally biased toward sim-
plifications. Many simplifications had been practical before
the Encyclopedia of DNA Elements (ENCODE) Project
(5) probed the complexity of transcriptional regulation. In
the lac operon and similar prokaryotic models, only a few
agents regulate each target gene (6). These models were ex-
trapolated to higher eukaryotes, which regulate gene expres-
sion by over a thousand sequence- or shape-specific tran-
scription factors, histone modifying enzymes and chaper-
ones (for brevity, TRs; 7). To handle this complexity, di-
verse concepts of master regulators were introduced. This
term occurs in over 28 700 publications, two-thirds of which
are related to cancer or cellular differentiation according to
our full-text Scopus search. We present multiple lines of ev-
idence that typically, rather than singular master regulators
or oligarchies, large numbers of TRs regulate genes. We re-
port and test our pluralistic and stochastic, minimally bi-
ased computational models. Stochastic is defined as ‘par-
tially randomly determined; a process that follows some
random probability distribution or pattern, so that its be-
havior may be analyzed statistically but not predicted pre-
cisely’ (8) (quoted verbatim in the Oxford English Dictio-
nary as well). At first glance, stochastic processes may ap-
pear vague. Inherently, they are more difficult to under-
stand, reproduce and verify than comparable deterministic
processes. Hence demanding high reproducibility leads to
ignoringmid-to-low probability events.However, stochastic
models allow for more accurate predictions than determin-
istic simplifications. For example, differentiated fibroblasts
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can be reprogrammed into pluripotent stem cells in multi-
ple ways (9). OCT4 and SOX2, two essential but insufficient
agents, along with either KLF4 andMYC (10) or NANOG
and LIN28 (11) can induce such reprogramming. Stochas-
ticity means that either KLF4 and MYC or NANOG and
LIN28 can bind in partially random processes (but with
similar effects). These four TRs bind to pluripotency tar-
gets with probabilitiesmuch below certainty but higher than
those TRs that cannot induce pluripotency. In this well-
established example, deterministic master regulators were
replaced by stochastic regulation (12). Similar probabilistic
patterns form the very essence of this publication.
A theory of transcriptional regulation is presented which
is consistent with our new results reported here:
 20–25 TRs bind reproducibly in ≈800 000 co-expressed
gene pairs, indicating pluralistic regulation.
 20 or more TRs are needed to predict transcript levels of
cytoplasmic ribosomal protein genes (cRPGs).
 TR binding shows stochastic enrichment patterns in
cRPGs compared to high-expression non-ribosomal
genes (HE-NRGs).
Pluralistic and stochastic gene regulation is also sup-
ported by a novel synthesis of earlier observations:
 Cellular levels, location, activity and binding of TRs and
polymerases undergo major fluctuations
 Transcription bursts and pauses even in the genes of TRs
themselves (11,13–16)
 A wide variety of ≈1700 human DNA-associated pro-
teins have evolved and been preserved (7)
 Transcription factors bind with different strength and
regulatory effect to highly variable DNA motifs/shapes
(17)
 Several double knockout mutants of TRs are viable (18)
 Several TRs have been replaced during evolution (Table
1) and their binding sites have been rewired even between
human and mouse (19).
Surprisingly, as we will show in the Discussion, concepts
of master regulators have already evolved from strict hier-
archies to more participative regulation. We continue this
trend by integrating the above observations with highly so-
phisticated stochastic models and computational simula-
tions of transcriptional regulation (9,13,20–26), which were
partly validated by experiments (16). To help the experimen-
tal community to embrace stochastic gene regulation, we
propose a theory of widespread pluralistic and stochastic
regulation based on the above wide spectrum of evidence.
MATERIALS AND METHODS
We analyzed six human and two murine cell lines for
which twenty or more regulators have been mapped by
the (mouse) ENCODE Project to the hg19, hg38 and mm9
genome assemblies. Two pairs of cell lines are comparable
across human and mouse: myelogeneous leukemia (K562
andMEL) and lymphoblastoid (GM12878 and CH12.LX).
Additional human cell types include embryonic stem cells
(h1-hESC1), hepatocarcinoma (HepG2), adenocarcinoma
(A549) and cervical cancer (HeLa-S3) cells. Pseudogenes
were eliminated, leaving 98 human and 87 mouse cRPGs
and 84 human and 76 mouse mRPGs (Supplementary Ta-
ble S1). cRPGs and mRPGs were compared to either all
non-ribosomal genes (NRGs), or their subset, the HE-
NRGs (Supplementary Table S2). We compare cRPGs to
169 human and 107 mouse HE-NRGs, the latter defined
as genes expressed at higher levels than the least inten-
sively expressed 25% of cRPGs in the Expression Atlas
(27). All data have been stored in our MySQL relational
database and queried by a PERL Database Interface li-
brary and scripts. The human part of theMySQLDatabase,
its documentation, and all the gene pairs with the number
of jointly bound and separately bound TRs, are available
at our web site: https://git.unl.edu/sladunga2/genereg/tree/
master. Other data can be obtained upon request.
TR binding site observations derived from chromatin
immunoprecipitation combined with deep sequenc-
ing (ChIP-Seq) were downloaded from the ENCODE
web sites (https://www.encodeproject.org). Gene co-
ordinates and annotations were taken from the EN-
SEMBL annotations (Homo sapiens.GRCh37.59.gtf and
Mus musculus.NCBIM37.67.gtf). From among over-
lapping gene annotations, the longest splice variant was
chosen. Binding sites were mapped to genes as follows:
when a binding site was localized within a gene’s coding
sequence or its up- or downstream 5000 base pair envi-
ronment (excluding potentially overlapping genes), the
binding site was associated with the gene. Five thousand
base pairs represent a compromise between the inclusion of
not overly distant enhancer regions and the minimization
of the number of TRs that do not affect the transcription of
the particular gene. To examine the impact of selecting the
longest coding regions with 5000 base pair upstream and
downstream segments (Gene5kb), we compared the results
to the most frequent transcripts and to predicted 600 base
pair promoter regions in K562 cells (Supplementary Infor-
mation, Figure S4 and Tables S4 and S5). The predicted
promoter regions largely reproduced the Gene5kb patterns
of enrichments although with higher fold changes.
Statistical analyses
High genewise counts of single TRs allowed evaluating the
statistical significance of enrichment using the Wilcoxon–
Mann–Whitney test. Due to the lower genewise counts
of TR dimers and trimers, enrichment was assessed using
Fisher’s exact test. Both tests are robust against large dif-
ferences in sample size. Unless otherwise noted, all results
reported here are statistically significant at the 0.01 level af-
ter multiple test correction by tailwise False Discovery Rate
(28).
Statistical/machine learning models
How many TRs are necessary to relatively accurately pre-
dict transcript levels from TR binding sites? To answer
this question, we use Least Angle Regression (LARS) (29).
LARS applies ordinary least squares to minimize the sum
of the absolute values of weights assigned to generalized
linear models. This parsimonious feature works as Occam’s
razor by regressing transcript levels using the fewest possi-
ble TRs. LARS performs cross-validation, i.e. training the
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Table 1. Few regulators of human cRPGs have orthologs in Saccharomyces cerevisiae. A few double knockout mutants of the orthologous mouse genes
are still viable
Regulator Mouse mutant phenotype





KAT2A GCN5 lethal reduced transcription elongation
ETS1 partially lethal phenotype
ELK1 mostly normal normal
GTF2B SUA7 lethal ?
ZZZ3 lethal lethal
TAF1 TAF1 phenotype
TAF7 TAF7 lethal phenotype
ATF2 ATF2 phenotype phenotype
HDAC6 HDA1 normal normal
RCOR1 SNT1 lethal phenotype
NFKB1 phenotype phenotype
CEPB lethal normal




CTCF CTCF lethal phenotype
MAFF lethal phenotype
NELFE ? phenotype
NFYB HAP3 ? phenotype
NRF1 lethal phenotype
RFX5 phenotype phenotype
SETDB1 SET2 lethal phenotype/lethal
models on one subset of input data and testing performance
on the complementary subset. Transcript levels were taken
from the Genevestigator database (30) and from the human
and mouse ENCODE experiments (31).
RESULTS
Genome-wide functional pluralistic TR binding in the human
genome
We found that TR binding sites were about twice as highly
reproducible in 799 695 co-expressed human gene pairs than
in 100 000 independently expressed genes in six human cell
types. We compared five co-expressed and one indepen-
dently expressed gene sets: all 4851 gene pairs within cRPGs
(Supplementary Table S1), all 3486 pairs of mitochondrial
ribosomal protein genes (mRPGs, Supplementary Table S1)
and all 14 196 pairs high-expression NRGs (HE-NRG’s,
Supplementary Table S2). Pseudogenes were eliminated.We
considered a gene as a HE-NRG if its median RNA-seq
transcript level exceeds the 25th percentile of the transcript
levels in cRPGs in the ExpressionAtlasDatabase (32) (Sup-
plementary Table S2, Materials and Methods). We also an-
alyzed 17 846 pairs of very strongly co-expressed genes (R≥
0.9, NRG A’s); 759 316 pairs of strongly co-expressed (0.9
> R ≥ 0.8) genes (NRG B’s), and a sample of 100 000 in-
dependently expressed (abs(R)< 0.1) gene pairs (NRG C’s,
Figures 1 and 2). Co-expression was measured by Pearson
correlation coefficients of transcript levels for each pair of
human protein-coding gene over 120 diverse samples in the
Expression Atlas (27) (see Materials and Methods).
We quantified the reproducibility of binding for each TR
using a simple adaptation of the Jaccard coefficient: J = n2n1
Here n2 is the number of gene pairs where the TR in ques-
tion is observed in both genes of the pair and n1 is the num-
ber of gene pairs where the TR is observed in at least one of
the two genes.
First, we examined individual TRs and their binding
sites. Binding events of PolII, YY1, (C)MYC, KDM5B,
TAF1, MAX, PHF8, ELF1 and MAZ are highly repro-
ducible (J ≥ 0.9) in NRG A’s, cRPGs and HE-NRGs (Fig-
ure 1). This high between-gene reproducibility is the lower
bound of ChIP-Seq reproducibility in the ENCODE exper-
iments (33), as discussed below. In NRG C’s however, the
reproducibility of most TRs remains below 0.25. The only
three exceptions are RUNX3, CTCF and RAD21.
Which TRs bind most reproducibly across cell types? To
answer this question, we compared the cell-wise distribu-
tions of the 50 most reproducibly bound TRs in the six gene
pair sets (Figure 2). In the five co-expressed sets of gene
pairs, about 25 TRs bind with a median reproducibility ex-
ceeding 0.5 compared to 0.23 in independently expressed
gene pairs. The interquartile ranges show that reproducibil-
ity is very similar in all cell types studied for RUNX3,
PolII, PHF8, IRF1, KDM5B, POU2F2, CTCF, RAD21
and CREB1, indicating largely cell-independent functions.
We found that twice as many regulators mapped repro-
ducibly in co-expressed pairs than in independently ex-
pressed gene pairs (Figure 3). This difference persists in-
dependently of gene length (Supplementary Information
and Figure S1). While co-regulated gene pairs tend to be
expressed at higher levels than independently transcribed
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Figure 1. High reproducibility of ChIP-Seq peaks in pairs of co-expressed
genes. Jaccard coefficients show reproducibility for the following sets of
gene pairs: cRPGs (n= 4851 pairs); mRPGs (n= 3486); HE NRGs (high-
expression NRGs, n = 14 196, see Materials and Methods); NRG A’s (di-
verse gene pairs co-expressed with R ≥ 0.9, n= 17 846); NRG B’s (diverse
gene pairs co-expressed with 0.9> R≥ 0.8, n= 759 316); and NRG C’s (a
sample of independently expressed, diverse gene pairs, abs(R) < 0.1, n =
100 000). TR binding in NRG C’s is about 50% less reproducible than in
co-expressed gene sets, indicating that a large portion of the binding events
in gene regions is functional.
ones, the effect of co-regulation on reproducibility is much
stronger than the level of expression (Supplementary Infor-
mation and Figure S2). In K562 cells, at least one gene of an
independently expressed (NRG C) pair binds to a median
of 62 TRs (Figure 3). Only 10 of these TRs bind to both
genes (J = 0.16). In highly co-expressed pairs (NRG A),
at least one gene of a pair binds to a median of 75 TRs.
Of these, 37 TRs bind to both genes (J = 0.49). The sig-
nificantly more reproducible binding (P < 10−16, Fisher’s
exact test) in co-expressed versus independently expressed
gene pairs indicates markedly pluralistic regulation.
Figure 2. TRs bindwith similar reproducibility in diverse human cells. Box
plots show the distribution of Jaccard coefficients for individual TR. Sets
of gene pairs are defined in Figure 1. In all co-expressed sets of gene pairs,
over 25 TRs bind with a median reproducibility exceeding 0.5. In inde-
pendently expressed gene pairs, reproducibility is only about 0.22, corre-
sponding to the magnitude of nonspecific TR binding. Highly significant
differences between co-expressed and independently expressed gene sets
(P< 10−256, Wilcoxon–Mann–Whitney test) indicate that even those TRs,
which bind in highly stochastic processes, may have biological roles.
Specific model: co-regulation of 98 cRPGS
We present a model based primarily on binding sites of less
than three hundred TRs in six human and two murine cell
types (Materials and Methods), gain/loss-of-function mu-
tants and evolutionary studies. The ENCODE Consortium
mapped these TR binding sites to the human and mouse
genomes using Chromatin ImmunoPrecipitation followed
by deep sequencing (ChIP-Seq; 5). Despite the strong co-
expression of ribosomal protein genes (RPGs, see below),
the observed binding patterns of TRs show differences be-
tween genes and cell types (Figure 5 and Supplementary
Figure S1). As we discuss in Supplementary Information,
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Figure 3. (A). More TRs bind to both genes in co-expressed gene pairs than in independently expressed pairs (NRG C’s, max(P)< 10−32, Wilcoxon test).
(B)Conversely, fewer TRs bind to only one gene in co-expressed gene pairs than in NRG C’s (max(P)< 10−32). The number of TRs that may be associated
with co-regulation depends on the TRs mapped in a cell type. The number of TRs implicated in co-regulation ranges from 25 (in A549 and GM12878 cells)
to over 50 (in HeLaS3, HepG2 and K562 cells).
these differences are largely due to stochastic TR binding,
not to experimental error.
To increase confidence and to estimate experimental er-
ror in TR binding site observations and to narrow the gray
zone, it would be ideal to map all regulators in tens of
ChIP-Seq replicates for several cell types. However, such a
megaproject would cost multiples of the ENCODE Project
Consortium’s budget. To increase confidence without as-
tronomic costs, we analyze a relatively homogeneous sub-
population of genes, which are tightly co-regulated to min-
imize waste in synthesizing stoichiometric amounts of ri-
bosomal proteins (34). Each gene serves as an experimen-
tal unit, analogously to clinical trials, where individual pa-
tients are not replicates but experimental units, which also
facilitate drawing robust conclusions (35). Dispersed across
22 chromosomes, the 98 cytoplasmic RPGs (cRPGs) form
the largest co-expressed gene network in the human genome
(Figure 4 and Supplementary Table S1) (36,37). Their vital
importance is another major advantage: viable null mutants
of a TR indicate that the TR is not necessary for cRPG ex-
pression.
RPG co-regulation has been reported a quarter century
ago (36) and in 2006 (37) based on very limited data sets.
As the tight co-expression of RPGs is critical to our results,
it is necessary to confirm and quantify RPG co-expression
by Pearson correlation coefficients on a large data set. For
every possible pairs of RPGs across 28 032 microarray sam-
ples in the Genevestigator Database (30), the median of the
correlation coefficients is as high as 0.788 for cRPGs and
0.514 for mRPGs (Figure 4). The probability of such co-
expression across 28K samples is less than 10−256. Its most
plausible cause is co-regulation. Imperfect correlations are
likely due to possible translational efficiencies and the about
one hundred extraribosomal functions that RPs perform
(38). However, as extraribosomal RP accumulation evokes
nucleolar stress and potentially, cell cycle arrest, most cy-
toplasmic RP molecules are constrained to the ribosomes
and the nucleoli (39). Co-expression is not due to constitu-
tive expression as cells repress or induce RPG transcription
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Figure 4. Confirmation of tight RPG co-expression across a wide range of conditions and cell types. (A) Base 2 logarithms of transcript levels (horizontal
axis) are shown in arbitrary but normalized units from 28,032 Affymetrix microarrays from the Genevestigator Database (30). Transcripts are over hun-
dredfold more abundant in cRPGs than in mRPGs and also vary between families of RPGs. (B) Pearson correlation coefficients (R) for cRPG transcript
levels for each RPG pair indicate that variations in transcript levels are reproducible and tightly correlated. The high median correlation of 0.7875 for all
cRPGs is very likely due to co-regulation. High co-expression is in accordance with the earlier observation that only a small proportion of RP molecules




























































































































































































































































































































































































































































































































































































































Figure 5. Stochastic TR binding to DNA does not show evident master
regulators. The unfiltered numbers of observed binding sites for individual
TRs (c) in cytoplasmic andmitochondrial RPGs in humanK562 cells. Sta-
tistical preferences for several TRs emerge despite considerable random-
ness, which is partly due to experimental noise. For scalability, log2(c +1)
values are shown. Stochastic TR binding is also confirmed for all other an-
alyzed human and mouse cell types (Supplementary Figure S3). The net-
work of cRPG regulation also shows rich and highly variable binding of
TRs to diverse cRPGs (Supplementary Figure S5).
in response to changes in energy levels and nutrient avail-
ability (37,40,41). Were co-regulation a deterministic pro-
cess, translational efficacy identical, extraribosomal func-
tion, experimental error and nonfunctional binding absent,
identical TRs would bind in identical amounts to all of the
98 cRPGs. In sharp contrast, the observed distribution of
TRs in six cell types shows a mixture of experimental error
and highly stochastic binding of TRs in diverse human cells
(Figure 5 and Supplementary Figure S1).
We systematically compared TR binding sites in cRPG
to those of all non-ribosomal genes (NRGs) as well as HE-
NRGs. We searched for DNA-bound master regulators for
cRPGs but could find none. We looked for strong correla-
tions between TR binding and cRPG transcript levels but
none exceeded 0.45. Binding sites of ≈20 regulators were
needed to accurately predict cRPG transcript levels by ma-
chine learning. Most TR knockout mutants in mice are
viable (18) indicating that these cannot be necessary con-
trollers of protein synthesis. On the evolutionary scale, the
most important RPG regulators in S. cerevisiae does not
have mammalian orthologs and the two third of the mam-
malian cRPG regulators do not have orthologs in fungi (Ta-
ble 1). Instead of masters, we found that only RNA Poly-
merase II (POL2), CTCF, MYC, YY1 and IRF1 bind to
most cytoplasmic and mitochondrial RPGs in K562 cells
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tary Figure S3). None of these TRs are specific to cRPGs
and the rest of TRs bind to RPGs in stochastic patterns
(Figure 5).
We examined peaks of binding sites for each TR sep-
arately, regardless of overlapping peaks predicted from
ChIP-Seq experiments (5), and for brevity, called them sin-
gle TRs. We also analyzed pairs and triplets of overlapping
peaks of distinct TRs and named them putative dimers and
trimers, regardless of overlaps with yet other TRs.We called
them putative as individual peaks are ‘snapshots’ taken at
different times and from different samples, hence some of
these binding events may occur in different times.
Enriched TR complexes indicate pluralistic and stochastic
regulation and signal integration
We observed statistically highly significant enrichment of
several TRs, hundreds of heterodimers and tens of thou-
sands of trimers in cRPGs as compared to HE-NRGs
and/or all NRGs (Figure 6 and Supplementary Tables S6–
S11). Unless otherwise mentioned, we compared cRPGs
to HE-NRGs and all comparisons were significant at the
P ≤ 0.01 level (Wilcoxon or Fisher’s Exact test, see Ma-
terials and Methods) followed by multiple test correction
using tail-wise False Discovery Rate (28). We present ev-
idence that these enrichment patterns indicate pluralistic
and stochastic integration of external and cellular signals
and regulatory mechanisms that are far more complex than
earlier reported cis-regulatory modules (42).
For the biological roles of these complexes, we extrapo-
lated from the roles of individual TRs based on previous ex-
periments to the functions of themultimolecular complexes.
These extrapolations provide a reasonably informed hypo-
thetical framework to guide future experiments.
Importantly, the enriched di- and trimers include sev-
eral well-studied TRs that have not yet been implicated in
RPG regulation. Of these, SIX5 (a.k.a. DMAHP or BOR2)
preferentially binds together with MYC, CHD1, TAF7,
GTF2B, and with cohesin constituents including RAD21,
CTCF, SMC3 and ZNF143. Consistent with SIX5 roles in a
wide array of disorders (43,44), in one or more of the six hu-
man cell types studied, SIX5 binds to 6,779 protein-coding
genes. One could expect that homozygous knockout mu-
tants of such a wide-spectrum TR to be lethal. However,
both the murine (44) and Drosophila (45) null mutants are
impaired in organ development but still viable. Because ri-
bogenesis is critical to protein synthesis, viable null mutants
indicate that the ribosome-specific functions of SIX5 can be
substituted by other TRs. This and the highly significant en-
richment of SIX5 and its complexes show that SIX5 has a
stochastic contribution to cRPG regulation, which is robust
against SIX5 mutations.
Similarly, the highly enriched BRCA1 (Figure 6) has
not been implicated in direct RPG regulation. Indirectly,
BRCA1 is known to interact with the nucleoli and the ri-
bosomal protein RPSA (46) to suppress the cell cycle upon
DNA damage (47). Preferential co-binding of BRCA1 with
CTCF and RAD21 indicates a role in modulating chromo-
some conformation (Figure 6). Preferred association with
GABP1, a known integrator of cellular signaling pathways
(48) suggests that GABP1 may interact with BRCA1 to
downregulate cRPGs under adverse conditions.
Specific pre-initiation complexes (PICs)
We extendRPG-specific PICs reported earlier (49) with sev-
eral novel stochastic patterns. The strong enrichment of the
transcriptional activator KAT2A (GCN5) indicates that it
contributes more to the regulation of cRPGs than to most
other genes including HE-NRGs. By acetylating histones,
KAT2A prepares the chromatin for intensive transcription.
Like HDAC6, one of its antagonists, KAT2A has been con-
served between yeast and mammals (50). GCN5, its or-
tholog in yeast, is known to regulate RPGs directly (51).
KAT2A is scaffolded to histones by the similarly enriched
ZZZ3. This latter protein is specific to ATAC and only ei-
ther ATAC or S(T)AGA, but not both, can bind to a highly
expressed gene (52). Thus, ZZZ3 enrichment (Figure 6, and
Supplementary Tables S6–S11) indicates strong preference
for the ATAC complex in cRPGs. As intrinsically disor-
dered regions within KAT2A are known to initiate the for-
mation of PICs (53), we speculate that KAT2A’s preferen-
tial associations may orchestrate the formation of RPG-
specific PIC’s. Preferential association with MYC (Figure
6 and Supplementary Tables S8–S11) is consistent with
the need for KAT2A-mediated histone acetylation to re-
cruit MYC (54). MYC, a widespread nonspecific regula-
tor of RPGs in vertebrates, has similarly extensive disor-
dered transactivation domains (55). In vitro, these domains
can recruit hundreds of regulators but in vivo, the interac-
tors are constrained by the co-bound partners and adjacent
DNAmotifs (15,56). MYC, its activator, MAX, and repres-
sor, MXI1 appear to interact with TAF7, HDAC6, REST,
NELF (RDBP) and BRCA1 (Figure 6, Supplementary Ta-
bles S6–S11). Such complex binding events indicate a net-
work far exceeding theMAX/MYC/MXI1 axis for the reg-
ulation and deregulation of oncogenic activity. In a posi-
tive feedback loop, KAT2A acetylates histones in the genes
of MYC, Yin Yang 1 (YY1) and other direct regulators of
RPGs. Subsequently, MYC induces the KAT2A gene (57).
Enriched complexes of the histone deacetylase HDAC6 or
similar agents can break this positive feedback loop.
The robust enrichment ofHDAC6 (Figure 6, Supplemen-
tary Tables S6–S11) raises the possibility that its influence
on the cell cycle (58) may be partly mediated via the reg-
ulation of ribogenesis. HDAC6 preferentially co-binds with
PolII, P300, estrogen receptor, RUNX2, NFB andHSP90;
an activity likely to be organized by the ubiquitin-binding
domain of HDAC6 (59). Despite the fundamental roles of
HDAC6, its null mutants display normal phenotype both
in Drosophila (60) and mouse (61), strongly indicating that
other enzymes, possibly paralogous HDAC family mem-
bers, can effectively perform HDAC6 functions.
The strongly enriched overlapping peaks of KAT2A and
chromodomain helicase DNA binding protein 1 (CHD1)
may indicate coupled histone acetylation and methylation
(62). This dimer and its superset with ZZZ3 are known
to evict nucleosomes to facilitate the passing of the tran-
scriptional machinery (63). KAT2A also forms enriched
di- and trimers with TBP/TRF2-associated factors TAF1
and TAF7. These factors form enriched complexes with
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Figure 6. cRPG regulatory binding events show highly specific and statistically significant patterns of enrichment or depletion of single transcriptional
regulators, putative TR heterodimers and heterotrimers. Human cRPGs are compared to HE-NRGs and NRGs in separate panels. For single TRs, the
significance of enrichment was assessed by the Wilcoxon–Mann–Whitney test, for dimers and trimers, by Fisher’s Exact Test. Multiple test corrections
were performed using Benjamini and Hochberg’s False Discovery Rate (28). Numerical data are available in Supplementary Tables S4–S8. (A) Single
TRs, cRPGs versus HE-NRGs. (B) Single TRs, cRPGs versus all NRGs. (C) Heterodimers, cRPGs versus HE-NRGs. (D) The 50 most highly enriched
heterodimers, cRPGs versusHE-NRGs. (E)Heterodimers, cRPGs versus all NRGs. (F)The 50most highly enriched heterodimers, cRPGs versus all NRGs.
(G) Heterotrimers, cRPGs versus HE-NRGs. (H) The 50 most highly enriched heterotrimers, cRPGs versus HE-NRGs. (I) Heterotrimers, cRPGs versus
all NRGs. (J) The 50 most highly enriched heterotrimers, cRPGs versus all NRGs.
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KAT2A, MYC, MAX, MXI1, Pol II, SIX5, YY1, G2F2B,
ZZZ3, IRF1, CHD1 and ZNF143 (Figure 6).
GTF2 subunits are among the most enriched regulators
(Figure 6). GTF2 is known to link the TFIID complex to
Pol II (64).We found that several jointmembers of the quan-
titative regulator complexes TFIID and S(T)AGA com-
plexes are enriched in RPG promoters (Figure 6). Taken
together, these observations show that PICs of RPGs dis-
play significantly different distributions of regulators than
PICs of other genes including HE-NRGs.
Pol II is enriched in cRPGs compared to NRGs, but
not compared to HE-NRGs (Figure 6 and Supplementary
Tables S6–S11). An inducer of polymerase pausing, RD
RNA binding protein (RDBP a.k.a. NELF) is enriched in
cRPGs relative to NRGs (Supplementary Tables S6–S11)
but not compared to HE-NRGs. Pausing is known to coun-
teract nucleosome reconstitution hence to prepare the chro-
matin for active transcription (65). On this basis, we spec-
ulate that RPG-specific PICs and transcriptional machin-
ery modulate polymerase performance and pausing. Re-
lief from pausing allows rapid RPG induction in timely
response to improved growth conditions. In cancer cells,
the MAX-MYC dimer relieves Pol II from pausing and
amplifies transcription (66). In both malignant transfor-
mation and experimental overexpression, MYC and MAX
may overinduce thousands of active genes by interacting
with members of the basal transcriptional machinery dur-
ing PIC formation (67). Under such conditions, MYC and
MAX indeed act as master regulators. We found that MYC
and MAX bind to 148 of the 183 human RPGs in at least
one of the six major cell lines (Figure 5 and Supplemen-
tary Figure S1). Unlike MAX, MYC by itself is enriched
in RPGs relative to both HE-NRGs and NRGs. In differ-
entiated cells, MAX forms the four most enriched pairs
with REST, G2F2F1, KAT2A and ZNF143, followed by
KAT2A MAX (Figure 6). PIC constituents MYC, MAX,
KAT2A, TAF1, TAF7 and SIX5 form the most enriched
triplets with the sole exception of A549 cells (Figure 6).
These observations and the presence of MYC and MAX
in mRPGs, which are expressed at hundredfold lower levels
than cRPGs (Figure 4) indicate MYC and MAX functions
that are not related to intensive transcription.
Stochasticity is the most plausible resolution for the os-
tensible controversy regarding the ternary complex factor
ELK1. Despite its high enrichment, ELK1 is redundant for
the regulation of ribogenesis and other processes. Its dele-
tion mutants in mice are not impaired in immune reaction,
brain and spleen function (68). Were ELK1 roles determin-
istic, it would be either enriched and essential or unenriched
and unnecessary. Instead, we observed enrichment because
it frequently but not necessarily regulates cRPGs. TRs like
ELK1 can be substituted by other TRs in stochastic pro-
cesses.
The tumor suppressor REST is enriched in cRPGs as
compared toNRGs both as amonomer andwhen co-bound
with MYC, STAT5A, Pol II, TAF7, TCF3 and TAF1 (Fig-
ure 6 and Supplementary Tables S6–S11). The enriched
complex of IRF1, yet another tumor suppressor, withMYC
and Pol II may counteract the hyperactivation of the cell cy-
cle by inhibiting MYC (69). These negative feedback mech-
anisms are critical to cRPG regulation.
Figure 7. Accurate prediction of transcript levels by Least Angle Regres-
sion (29) models (see Materials and Methods) requires binding sites of no
less than 20 TRs in human and mouse cell types. Cross-validation predic-
tion accuracy is shown in the function of the number of TRs selected by
Least Angle Regression.
Machine learning models of transcriptional regulation
Next we asked: how many TRs bound to cRPGs can pre-
dict the observed transcript levels? To avoid inaccurate pre-
dictions on untrained observations (known as overtrain-
ing), machine learning methods need to be trained on about
three-to-five times fewer carefully selected TRs than genes.
For example, K562 cells transcribe 98 cRPGs. Therefore
we had to select subsets of 98/4–25 or fewer TRs to max-
imize prediction accuracy for untrained observations. For
this purpose, Least Angle Regression (LARS) (29) provided
for the highest accuracy (seeMaterials andMethods). Note
that TR selection (in computer science terms, feature se-
lection) methods maximize regression accuracy, not the bi-
ological importance of the TRs. For example, if two or
more TRs, such as the mandatory components of the PIC
or transcriptional machinery, bind to similar genes in sim-
ilar quantity under similar conditions, only one is neces-
sary for regression despite similar biological necessity of
the other proteins. For this reason, regression typically de-
mands fewer TRs than transcriptional regulation, making
our estimates for the numbers of necessary TRs conserva-
tive.
LARS achieved 74% cross-validation prediction accu-
racy for K562 cells using binding sites of 20 TRs (Figure
7, Supplementary Table S5). Higher accuracy would de-
mand more TRs but the number of cRPGs limits the num-
ber of TRs that can account for robust predictions. These
findings implicate a minimum of twenty TRs in the regula-
tion of cRPGs in human and mouse. As several TRs cor-
relate moderately (0.3 < R < 0.45) with transcript levels
(Figure 8), were these TRs acting independently, four TRs
would account for almost all of the regulation and would
allow for accurate predictions. This is not the case, indicat-
ing strongly interdependent effects of these agents. There-
fore none of the above TRs is sufficient for the regulation of
cRPGs under the conditions of the ChIP-Seq experiments.
Despite moderate correlations between the binding of in-
dividual TRs and transcript levels, the complexes that reg-
ulate cRPG transcription contain no less than 29 different
TRs which are both enriched and predictive for cRPG ex-
pression in one or more cell type studied.
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Figure 8. Nomaster regulator emerges from the moderate correlations be-
tween TR binding sites and transcript levels in cRPGs. Transcript levels for
human K562 and GM12878 cells were taken as the average transcript lev-
els from the Genevestigator Database (30); for mouseMEL and CH12.LX
cells RNA sequencing transcript levels were calculated from rawdata of the
mouse ENCODE Project (31).
DISCUSSION
We report a general theory of pluralistic and stochastic reg-
ulation of PolII-mediated transcription in human. This the-
ory is a synthesis of our above results with a broader spec-
trumof published evidence. In our studies,most of the≈800
000 tightly co-expressed gene pairs are bound reproducibly
by over twenty TRs, indicating widespread pluralistic regu-
lation. In RPGs, the largest co-expressed network of genes
in human, observed TR binding sites vary greatly among
individual RPGs (Figure 5 and Supplementary Figure S1)
despite their tight co-expression (36,37). A particular RPG
in a particular cell type can be regulated by very diverse
TRs. This variation significantly exceeds the level of ChIP-
Seq error. We searched for DNA-associated master regula-
tors of cRPGs but could find none. We looked for strong
correlations between TR binding and cRPG transcript lev-
els but none exceeded 0.45. Binding sites of ≈20 regula-
tors were needed to accurately predict cRPG transcript lev-
els by machine learning. Most TR knockout mutants in
mice are viable (18) indicating that these cannot be neces-
sary controllers of protein synthesis. On the evolutionary
scale, the most important RPG regulators in S. cerevisiae
does not have mammalian orthologs and the two third of
the mammalian cRPG regulators do not have orthologs
in fungi (Table 1). Instead of master regulators, we found
significant enrichment of 41 individual TRs, 700 putative
dimers, and 9827 trimers in cRPGs compared to HE-NRGs
(Supplementary Tables S6–S11). The probability of the ran-
dom occurrence for such strong patterns is close to zero.
This enrichment shows that a large number of TRs, dimers,
trimers, and likely higher order complexes collectively regu-
late cRPGs. MYC, NFB and other widely bound TRs act
as regulatory hubs recruiting other TRs. Under most nor-
mal, stress and disease conditions, repressors like HDAC6,
MXI1, NELF1, REST, IRF1 and BRCA1 prevent regula-
tory hubs from becoming uncontrolled master regulators.
When negative feedback fails,MYC andMAXmay become
master regulators and amplify the transcription of thou-
sands of genes in cancer (66). The observed stochastic TR
binding and interactions are more robust against regulatory
malfunctions (such as mutations and evolutionary substitu-
tion of regulators and their binding sites) than rigid hierar-
chies controlled by masters (70).
We also found that accurate predictions of cRPG tran-
script levels demand a minimum of 20 regulators. This is in
concordance with the viability of null mutants for several
orthologous murine (18) and Drosophila TRs (45). These
observations show that TRs regulating cRPGs can substi-
tute each other to a large extent. A high number of TRs,
even some of those that bind to thousands of genes, are not
critical to survival (71). In a study of the control of growth
arrest and differentiation in a leukemia cell line, none of the
52 TRs knocked down by short interfering RNAs proved to
be as necessary (master) regulators (72).
Many regulators disappear and others emerge during
evolution. Despite the vital role of ribogenesis and the
strong conservation of most RPs in eukaryotes (73), their
regulators and regulator binding sites have evolved rapidly
(74). We have implicated 27 TRs in the regulation of
cRPGs. This is the union of highly predictive TRs in ma-
chine learning experiments and the enriched single TRs
in all six human cell types. We hypothesize that sev-
eral other TRs contribute to the governance of cRPG
expression. The confirmation of this hypothesis requires
additional experiments. Of the 27 TRs implicated here,
only 11 have apparent orthologs in Saccharomyces cere-
visiae (CTCF, KAT2A, GTF2, TBP, TAF1, TAF7, ATF2,
HDAC6, RCOR1, NFYB and SETDB1; Supplementary
Table S6). MYC binds to most RPGs in mammals (56)
but neither MYC nor its prime interactors, MAX and
MXI1, nor the also widely bound BRCA1 have detectable
homologs in yeast (Supplementary Table S6, Wu, Y.-C.,
Bansal, M.S., Rasmussen, M.D., Herrero, J. and Kellis, M.
(2014) Phylogenetic Identification and Functional Char-
acterization of Orthologs and Paralogs across Human,
Mouse, Fly and Worm. bioRxiv, doi:10.1101/005736). In
S. cerevisiae, RAP1 is one of the most important regula-
tors of RPGs; whereas in another yeast, Candida albicans,
TBF1 plays a similar role (75). Neither have detectable ho-
mologs in humans. Such extensive gains and losses of TRs
have not caused lethal impairments to protein synthesis in
the ancestors of contemporary species, indicating that these
TRs were not necessary at some times and in some lin-
eages. Compared to prokaryotes and yeasts, over 1200 ad-
ditional TRs evolved in the lineage of mammals (7). The re-
sulting vast combinatorics also facilitates sophisticated re-
sponses to internal and external signals. For example, the
mTORC1 kinase complex governs RPGs by directly or in-
directly phosphorylatingMYC,YY1, STAT’s, JUN, histone
deacetylases, BRCA1, RAD21, ZZZ3, KDM5A and TAF1
(76,77). To a limited extent, even the mTORC1 kinase com-
plex can be substituted by the phosphatidylinositol 3-kinase
and ERK-MAP pathways (78,79).
DNA binding sites of transcription factors evolve very
fast. The resulting variability modulates the strength and
the regulatory effects of individual sites (17). As old bind-
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ing sites are transferred to new loci or deteriorate and new
sites emerge, a large part of the regulatory network changes
during evolution. Only 36%of themouse regulatory regions
(DNase hypersensitivity sites) maps to human regions and
only 14% of them are conserved in both content and po-
sition (19,31). Such mutations in regulatory regions are re-
sponsible for massive evolutionary rewiring of the regula-
tory networks.
In RPGs and 800 000 co-expressed gene pairs, regulatory
specificity is generated by as many as 20–25 TRs. The dis-
tribution of TR binding sites and associations follow sta-
tistical patterns ranging from strictly preferential to highly
random. A wide spectrum of stochastic protein–protein
and protein–DNA interactions are promoted by an unusual
abundance of intrinsically disordered domains in transcrip-
tion factors (15). TRs like MYC and KAT2A with ex-
ceptionally large intrinsically disordered domains (15) may
bind to a large variety of other regulators. Widely bound
TRs such as MYC and NFB recruit other TRs. These in-
teractions are built and broken in a matter of seconds (80),
further increasing probabilistic binding, which is the plau-
sible cause for burst-like expression patterns (14). Stochas-
tic TR binding may cause stochastic regulatory effects, in-
cluding pauses and bursts of transcription. The binding of
different TRs is considerably but not fully preferential and
is affected by random effects such as the availability and
Brownian motion of TRs in the nucleus (81).
Surprisingly, pluralistic and stochastic gene regulation
can be reconciled with what most recent authors call master
regulators. Masters can be defined as inducers of a cascade
of regulatory events that guide the cell cycle, cellular dif-
ferentiation and other biological processes (82). Note that
this definition requires neither necessity nor rigorous suffi-
ciency of the master for inducing a process or a phenotype.
As more and more TRs are implicated in the governance
of animal development, Chan and Kyba (83) pointed out
that ‘the genome might have more masters than servants’.
Hence the metaphor of masters taken from human societies
may lose its relevance.
With the emergence of regulatory information, authors
relaxed the concepts of master regulators. Originally, a mas-
ter regulator was defined as ‘a gene which. . . should not be
under the regulatory influence of any other gene’ (84). How-
ever, the ENCODE Project (85) demonstrated that even TR
genes are bound by numerous other TRs. According to a
somewhat later definition, master regulators are necessary
and sufficient agents for producing a phenotype or differen-
tial gene expression (72). Necessity means that no other TR
is sufficient and sufficiencymeans that no other TR is neces-
sary. As the number of genes is strictly controlled inMeta-
zoa (86), hundreds of nonfunctional TR genes would have
been eliminated. Second, being known targets of signaling
pathways, many of the implied ‘servants’ integrate and con-
vey a wide variety of cellular information to improve regu-
latory decisions (87).
Such a ‘dictatorial’ concept may be overly strict and sev-
eral proposed masters were not verified rigorously. Neces-
sity can be validated using homozygous knockout mutants
(18). For example, the transcription factor BCL11A is nec-
essary for the developmental stage-specific downregulation
of the  -globin gene as shown using BCL11A−/− trans-
genic mice (88). However, its sufficiency remains unproven
as DEAD and/or SIX6 may also be necessary for down-
regulation (88). Proving the sufficiency of individual can-
didates by overinducing the expression of their genes can
be problematic (89). In an ideal overinduction experiment,
no other specific regulator would bind to synthetic promot-
ers and enhancers, and no cofactors would be associated
with the candidate master. As such in vivo experiments are
hardly feasible in higher eukaryotes given that co-binding
specific regulators confound practical sufficiency tests. At
far beyond physiological levels, MYC andMAX flood low-
affinity DNA sites and outcompete repressors. This low-
specificity upregulation of several thousand genes (90,91)
is named as transcriptional amplification (66). Under such
conditions, MYC andMAX act as strict sense master regu-
lators.
Hierarchy may exist in the regulation of the transcrip-
tional regulators themselves. This complex network prob-
lem requires additional studies. Necessary and sufficient
masters including MyoD (92) and SCL (93) do exist even
under physiological conditions. However, their number
could be far lower than previously thought (83). Consid-
erably random effects were found even in the action of
classic masters including Bicoid, Hunchback, Caudal and
Nanos, which orchestrate the segmentation of Drosophila
embryos (94). Therefore, compared to deterministic ap-
proaches, thermodynamic models of multiple TRs predict
the transcription of segmentation-related genes more accu-
rately (95).
The concept of master regulators can be extended to sets
of a few TRs (96), which we call ‘oligarchies’. To prevent the
uncontrolled growth of oligarchies, we require that none of
the individual oligarchs is sufficient to induce a phenotype
but each of them is necessary. These criteria disqualify sev-
eral previous claims for master regulators and oligarchies.
In the fibroblast reprogramming example (9) mentioned in
the Introduction, OCT4 and SOX2 are essential but insuf-
ficient for reprogramming and none of the four TRs, KLF4
and MYC (10) or NANOG and LIN28 (11) is necessary.
Hence none of these six TRs is a strict sense master regula-
tor.
According to a Scopus search, over 28 700 publications
mention master regulators. Most authors use this metaphor
solely to indicate the well-established differential impor-
tance of TRs (85). Calling the most important TRs as ‘mas-
ters’ may be somewhat inaccurate, but this does not conflict
with stochastic and pluralistic regulation.
We recognize the limitations of our insight into the
vast complexity of transcriptional regulation. As of August
2015, the ENCODE Project (5) mapped about three hun-
dred of the ≈1700 DNA-associated proteins and a frac-
tion of histone modifications in human cells (7). False neg-
ative observations and unknown distal enhancer regions
(97) may lead to overlooking numerous regulator binding
sites. To a lesser extent, false positives also present a con-
cern. We have limited information about the differences in
the stability, lifespan and regulatory effects of TR binding
sites. Our stochastic and pluralistic model of gene regula-
tion is biased toward highly expressed genes with specific
transcriptional machinery. Another potential bias is that
cRPGs are governed by a higher number of TRs including a
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larger percentage of general regulators than most medium-
to-low-expression genes. ENCODE’s selection of TRs, am-
plification bias in ChIP-Seq, and phantom peaks may fur-
ther bias analyses including ours. However, using objective
statistics, machine learning methods, evolutionary observa-
tions and gain-/loss-of-function mutants, we reduced inter-
pretational and simplification bias.
In summary, the stochastic distribution of TR binding
sites across the human genome, the viability of null mutants
for most TRs and the evolutionary rewiring of the regula-
tory networks indicate the wide extent of stochastic regu-
lation. TRs bind to DNA and associate with each other
in partially random manner but with probabilistic prefer-
ences. Deterministic regulation cannot produce stochastic,
burst-like transcription. Stochastic mechanisms have a ma-
jor evolutionary advantage over rigid, deterministic sys-
tems. Positive Darwinian selection for increasingly adaptive
regulators (98) and binding site patterns improves adap-
tation to new environments and elevate organismal com-
plexity during evolution. Neither positive selection for mu-
tants with improved fitness nor negative selection against
less adaptive mutants was able to eliminate stochastic reg-
ulation. Also, degrading most of the ≈1700 human TRs to
mere ‘servants’ would eliminate robustness against muta-
tions, the large majority of regulatory repertoire, and hence
the pool for evolutionary adaptation. The ≈800 000 co-
regulated gene pairs and the cRPGs indicate that plural-
istic and stochastic mechanisms are widespread in the hu-
man and likely other genomes. This does not contradict
most of the≈28 700 publications that discussmaster regula-
tors in some relaxed sense. We recommend evaluating both
stochastic and more or less hierarchical regulation as well.
Sophisticated and minimally biased interpretations of tran-
scriptional regulation will guide us to understand the effects
of regulatory mutations in the millions of human genomes
soon to be sequenced (3) and to design therapeutic inter-
ventions.
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ChIP-Seq reproducibility and quality are critical to our conclusions. In the absence of 
“standards of truth”, experimental error cannot be quantified directly. Instead, reproducibility 
has been evaluated rigorously using Irreproducible Discovery Rate (IDR) (1). IDR evaluates 
the consistency of ranking for all peaks in a pair of ChIP-Seq duplicates. IDR is robust to the 
choice of the peak calling algorithm and its parameters. High ChIP-Seq standards used in the 
ENCODE experiments for highly localized “point-source” TR experiments required: an IDR ≤ 
0.01 (2), a minimum of two replicates, no less than 10 million mapped reads in each replicate, 
and secondary confirmation for antibody specificity (3). Note that the IDR criterion makes our 
assessments of stochasticity conservative. In addition to reproducibility analyses, ChIP-Seq 
peaks were also compared to negative controls obtained by nonspecific antibodies. Additional 
quality metrics such as the Fraction of Reads in Peaks (FRiP), strand cross-correlation, library 
complexity, and the fraction of nonredundant mapped reads in a data set are discussed 
elsewhere (3). Substandard replicates and experiments were removed from further analyses. 
Despite strict quality assurance, a gray zone remains between confidently called ChIP-Seq 
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peaks and experimental noise. False peaks may occur even in control datasets due to 
overrepresentation of reads from unknown copy number variants or amplification bias (4). 
Other “phantom” peaks may originate from the increased shearing efficiency of open 
chromatin (5). Numerous potentially false peaks have been removed from the ChIP-Seq 
datasets but an unknown number of them may have escape detection (2). Weak binding sites 
may escape detection, which requires more than 10 million mapped reads per replicate (6,7). 
The reasonably high quality of the ENCODE ChIP-Seq experiments have been confirmed by a 
recent study (2). 
TR binding in the most abundant transcripts and in promoter regions 
To examine the impact of selecting the longest coding regions with 5,000 base pair 
upstream and downstream segments (Gene5kb), we compared the results to the most 
frequent transcripts and to predicted promoter regions as well in K562 cells. The most 
frequent transcript for each gene was determined Cap Assessment of Gene 
Expression (CAGE) studies by the FANTOM Consortium (8). The most frequent 
transcripts (from the TSS to the end of the 3’UTR) contained as few as 65,951 TR 
binding sites (3.8 percent of all the 1,736,829 sites observed). Most of the binding sites 
in coding regions are flatly distributed due to the movement of the transcription 
machinery.  To address this issue, we used broad peaks from the Hudson Alpha 
Institute predicted by the SPP method (9). Unfortunately, the ENCODE Project has not 
published other broad peaks. Instead of peaks, one may analyze counts of sequencing 
reads but normalization remains an open problem.  Therefore a potentially large 
number of binding sites were missed within the transcripts. An average of ~3 binding 
site per gene is insufficient for any of our statistical analyses.  
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Next, we analyzed putative promoter regions. Promoter predictions are not available 
from the FANTOM Consortium (8).  In K562 cells, the average length of the combined 
ChromHMM (10) and Segway (11) predictions is as high as 1,165 base pairs. Such 
wide promoters would largely reproduce the Gene5kb analyses. For more conservative 
promoter predictions, we enumerated the binding sites for every transcription start site 
(TSS) for each gene. Following the conventions of the Eukaryotic Promoter Database 
(12), we included the 499 base pairs upstream and 100 base pair downstream of each 
TSS. We selected the most densely bound region as the putative promoter. Typically, 
this was different from the most abundantly transcribed TSS as indicated by CAGE. In 
the predicted promoter regions, 543,316 binding sites were mapped (31.3 percent), 
while in the 5,000 base pair regions of the longest transcripts, 653,386 binding sites 
(37.6 percent) were found. Taking into account the relatively small difference between 
the two datasets, our major analyses are based on Gene5kb.  This approach balances 
between avoiding sites with limited or no regulatory effects and including important 
regulators binding outside the promoter region including moderately distant enhancers. 
Narrowing the search space to putative promoter regions would have weakened our 
claim of not finding master regulators as they could bind to more upstream or 
downstream locations. 
Promoter regions show stronger enhancement of the same TRs as Gene5kb (Fig. S1 
and Tables S3-S5). This may indicate some combination of more specific TR binding, 
fewer less functional binding, and less ChIP-Seq noise due to nucleosomes in 
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promoters compared to Gene5kb.  TRA4, TAF7, and TAF1 show particularly stronger 
enrichment in promoter regions compared to Gene5kb. 
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Supplementary Figures 
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Figure S1. Reproducibility of TR binding between gene pairs improves very slowly with the 
combined length of exons and introns (for brevity, gene length).  Base 2 logarithms of the 
geometric means of gene lengths are displayed. The Jaccard similarity coefficient increases 
moderately with gene length for NRG_A’s, NRG_B’s, and NRG_C’s in six human cell types. 
Gene length is similarly distributed in all co-expression sets. 
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Figure S2. Transcript levels have small effects on the reproducibility of TR binding in co-
regulated and independently expressed gene pairs. Base 2 logarithms of the geometric mean 
of transcript levels are shown. Although transcript levels are mostly lower in NRG_C’s (non-
logarithmic median: 1.4, interquartile range [IQR]: 0.05 – 6.4) than in NRG_A’s (median: 44.9, 
IQR: 21.2 – 85.7, p < 10-32) and in NRG_B’s (median: 41.6, IQR: 20.2-73.3, p < 10-32), the 
regression line remains twice as high at most transcript levels in NRG_A’s and NRG_B’s than 
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Figure S3.  Stochastic TR binding to DNA does not show evident master regulators. The 
unfiltered numbers of observed binding sites for individual TRs (c) in cytoplasmic and 
mitochondrial RPGs in human K562 cells. Statistical preferences for several TRs emerge 
despite considerable randomness, which is partly due to experimental noise. For scalability, 
log2(c +1) values are shown. For K562 cells, see in-text Fig. 5. For network representation, see 
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Fig. S4. Enrichment or depletion of single TRs (A), putative TR dimers (B), and putative TR 
trimers (C). In genes and their 5kb environments (Gene5kb) and in the predicted promoter 
regions of K562 cells, we compared cRPGs to HE-NRGs. Gray color indicates TRs that are not 
significantly enriched/depleted, all other TRs are significantly enriched or depleted at the FDR 
≤ 0.01 level. Numerical fold change data are shown in Tables S3-S5. 
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Figure S5. The network of RPG regulation. RPGs are regulated by large and diverse sets of 
agents that are also implicated in the governance of the cell cycle and cancer. Edges 
represent binding of a TR to an RPG. Yellow circles represent small subunit RPGs, yellow 
rectangles stand for large subunit RPGs and green diamonds indicate regulators. Sizes of 
RPG icons are proportional to the number of bound regulators. Most RPGs are bound by a 
high number of regulators, and those that are not are likely variants or conditionally translated 
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genes. Sizes of green diamonds are proportional to the number of RPGs to which the TR binds. 
This Figure was drawn using Cytoscape (13).  
Supplementary Table Legends 
Table S1. Genes coding for functional cytoplasmic and mitochondrial proteins (A) in the 
human genome, and (B) in the mouse genome.  
Table S2.  Highly expressed non-ribosomal genes (HE-NRGs) in human and mouse, defined 
as genes expressed at higher levels than the least intensively expressed 25 percent of cRPGs 
in the Expression Atlas (26).  
Table S3. Enrichment of single TRs in genes and their 5kb environments (Gene5kb) and in 
the predicted promoter regions of K562 cells cRPGs compared to HE-NRGs. NS indicates TRs 
that are not significantly enriched/depleted, all other TRs are significantly enriched or depleted 
at the FDR ≤ 0.01 level. 
Table S4. Enrichment of putative TR dimers in genes and their 5kb environments (Gene5kb) 
and in the predicted promoter regions of K562 cells cRPGs compared to HE-NRGs. NS 
indicates TRs that are not significantly enriched/depleted, all other TRs are significantly 
enriched or depleted at the FDR ≤ 0.01 level. 
Table S5. Enrichment of putative TR trimers in genes and their 5kb environments (Gene5kb) 
and in the predicted promoter regions of K562 cells cRPGs compared to HE-NRGs. NS 
indicates TRs that are not significantly enriched/depleted, all other TRs are significantly 
enriched or depleted at the FDR ≤ 0.01 level. 
Table S6.  Enrichment of single TRs in cRPGs compared to HE-NRGs in human cell types in 
Gene5kb regions.  
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Table S7.  Enrichment of single TRs in cRPGs compared to all NRGs in human cell types in 
Gene5kb regions.  
Table S8. Enrichment of putative TR dimers in cRPGs compared to HE-NRGs in human cell 
types in Gene5kb regions. 
Table S9. Enrichment of putative TR dimers in cRPGs compared to all NRGs in human cell 
types in Gene5kb regions. 
Table S10.  Enrichment of putative TR trimers in cRPGs compared to HE-NRGs in human 
cell types in Gene5kb regions. 
Table S11. Enrichment of TR trimers in cRPGs compared to all NRGs in human cell types in 
Gene5kb regions. 
Table S12. TRs selected for most accurate prediction of transcript levels. Sets of 20 TRs 







































































Table S1. Genes coding for functional cytoplasmic and 











































































































































































































































































































Ensembl Gene ID Description HGNC symbol
ENSG00000011052 NME/NM23 nucleoside diphosphate kinase 2 [Source:HGNC Symbol;Acc:HGNC:7850] NME2
ENSG00000019582 CD74 molecule, major histocompatibility complex, class II invariant chain [Source:HGNC Symbol;Acc:HGNC:1697] CD74
ENSG00000034510 thymosin beta 10 [Source:HGNC Symbol;Acc:HGNC:11879] TMSB10
ENSG00000063046 eukaryotic translation initiation factor 4B [Source:HGNC Symbol;Acc:HGNC:3285] EIF4B
ENSG00000065518 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa [Source:HGNC Symbol;Acc:HGNC:7699] NDUFB4
ENSG00000065978 Y box binding protein 1 [Source:HGNC Symbol;Acc:HGNC:8014] YBX1
ENSG00000067225 pyruvate kinase, muscle [Source:HGNC Symbol;Acc:HGNC:9021] PKM
ENSG00000067560 ras homolog family member A [Source:HGNC Symbol;Acc:HGNC:667] RHOA
ENSG00000070756 poly(A) binding protein, cytoplasmic 1 [Source:HGNC Symbol;Acc:HGNC:8554] PABPC1
ENSG00000074800 enolase 1, (alpha) [Source:HGNC Symbol;Acc:HGNC:3350] ENO1
ENSG00000075415 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 [Source:HGNC Symbol;Acc:HGNC:10989] SLC25A3
ENSG00000075624 actin, beta [Source:HGNC Symbol;Acc:HGNC:132] ACTB
ENSG00000075785 RAB7A, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:9788] RAB7A
ENSG00000078369 guanine nucleotide binding protein (G protein), beta polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:4396] GNB1
ENSG00000080824 heat shock protein 90kDa alpha (cytosolic), class A member 1 [Source:HGNC Symbol;Acc:HGNC:5253] HSP90AA1
ENSG00000084207 glutathione S-transferase pi 1 [Source:HGNC Symbol;Acc:HGNC:4638] GSTP1
ENSG00000084234 amyloid beta (A4) precursor-like protein 2 [Source:HGNC Symbol;Acc:HGNC:598] APLP2
ENSG00000087086 ferritin, light polypeptide [Source:HGNC Symbol;Acc:HGNC:3999] FTL
ENSG00000088986 dynein, light chain, LC8-type 1 [Source:HGNC Symbol;Acc:HGNC:15476] DYNLL1
ENSG00000092199 heterogeneous nuclear ribonucleoprotein C (C1/C2) [Source:HGNC Symbol;Acc:HGNC:5035] HNRNPC
ENSG00000092841 myosin, light chain 6, alkali, smooth muscle and non-muscle [Source:HGNC Symbol;Acc:HGNC:7587] MYL6
ENSG00000096384 heat shock protein 90kDa alpha (cytosolic), class B member 1 [Source:HGNC Symbol;Acc:HGNC:5258] HSP90AB1
ENSG00000100097 lectin, galactoside-binding, soluble, 1 [Source:HGNC Symbol;Acc:HGNC:6561] LGALS1
ENSG00000100650 serine/arginine-rich splicing factor 5 [Source:HGNC Symbol;Acc:HGNC:10787] SRSF5
ENSG00000100823 APEX nuclease (multifunctional DNA repair enzyme) 1 [Source:HGNC Symbol;Acc:HGNC:587] APEX1
ENSG00000101439 cystatin C [Source:HGNC Symbol;Acc:HGNC:2475] CST3
ENSG00000102265 TIMP metallopeptidase inhibitor 1 [Source:HGNC Symbol;Acc:HGNC:11820] TIMP1
ENSG00000103363 transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B) [Source:HGNC Symbol;Acc:HGNC:11619] TCEB2
ENSG00000103495 MYC-associated zinc finger protein (purine-binding transcription factor) [Source:HGNC Symbol;Acc:HGNC:6914] MAZ
ENSG00000104529 eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) [Source:HGNC Symbol;Acc:HGNC:3211] EEF1D
ENSG00000104904 ornithine decarboxylase antizyme 1 [Source:HGNC Symbol;Acc:HGNC:8095] OAZ1
ENSG00000104964 amino-terminal enhancer of split [Source:HGNC Symbol;Acc:HGNC:307] AES
ENSG00000105373 glioma tumor suppressor candidate region gene 2 [Source:HGNC Symbol;Acc:HGNC:4333] GLTSCR2
ENSG00000105701 FK506 binding protein 8, 38kDa [Source:HGNC Symbol;Acc:HGNC:3724] FKBP8
ENSG00000106153 coiled-coil-helix-coiled-coil-helix domain containing 2 [Source:HGNC Symbol;Acc:HGNC:21645] CHCHD2
ENSG00000106211 heat shock 27kDa protein 1 [Source:HGNC Symbol;Acc:HGNC:5246] HSPB1
ENSG00000107223 endothelial differentiation-related factor 1 [Source:HGNC Symbol;Acc:HGNC:3164] EDF1
ENSG00000108518 profilin 1 [Source:HGNC Symbol;Acc:HGNC:8881] PFN1
ENSG00000108953 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon [Source:HGNC Symbol;Acc:HGNC:12851] YWHAE
ENSG00000109971 heat shock 70kDa protein 8 [Source:HGNC Symbol;Acc:HGNC:5241] HSPA8
ENSG00000110651 CD81 molecule [Source:HGNC Symbol;Acc:HGNC:1701] CD81
ENSG00000110717 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) [Source:HGNC Symbol;Acc:HGNC:7715] NDUFS8
ENSG00000110955 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide [Source:HGNC Symbol;Acc:HGNC:830] ATP5B
ENSG00000111640 glyceraldehyde-3-phosphate dehydrogenase [Source:HGNC Symbol;Acc:HGNC:4141] GAPDH
ENSG00000111669 triosephosphate isomerase 1 [Source:HGNC Symbol;Acc:HGNC:12009] TPI1
ENSG00000111678 chromosome 12 open reading frame 57 [Source:HGNC Symbol;Acc:HGNC:29521] C12orf57
ENSG00000111716 lactate dehydrogenase B [Source:HGNC Symbol;Acc:HGNC:6541] LDHB
ENSG00000111775 cytochrome c oxidase subunit VIa polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:2277] COX6A1
ENSG00000112695 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) [Source:HGNC Symbol;Acc:HGNC:2288] COX7A2
ENSG00000113558 S-phase kinase-associated protein 1 [Source:HGNC Symbol;Acc:HGNC:10899] SKP1
ENSG00000114942 eukaryotic translation elongation factor 1 beta 2 [Source:HGNC Symbol;Acc:HGNC:3208] EEF1B2
ENSG00000116288 parkinson protein 7 [Source:HGNC Symbol;Acc:HGNC:16369] PARK7
ENSG00000117450 peroxiredoxin 1 [Source:HGNC Symbol;Acc:HGNC:9352] PRDX1
ENSG00000117984 cathepsin D [Source:HGNC Symbol;Acc:HGNC:2529] CTSD
ENSG00000118816 cyclin I [Source:HGNC Symbol;Acc:HGNC:1595] CCNI
ENSG00000120885 clusterin [Source:HGNC Symbol;Acc:HGNC:2095] CLU
ENSG00000122566 heterogeneous nuclear ribonucleoprotein A2/B1 [Source:HGNC Symbol;Acc:HGNC:5033] HNRNPA2B1
ENSG00000123349 prefoldin subunit 5 [Source:HGNC Symbol;Acc:HGNC:8869] PFDN5
Table S2. Highly expressed non-ribosomal genes (HE-NRGs) in human and mouse were selected from the Expression Atlas 
Database (Kolesnikov et al., 2015).
Human HE-NRGs
ENSG00000123416 tubulin, alpha 1b [Source:HGNC Symbol;Acc:HGNC:18809] TUBA1B
ENSG00000125534 pancreatic progenitor cell differentiation and proliferation factor [Source:HGNC Symbol;Acc:HGNC:16142] PPDPF
ENSG00000125743 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa [Source:HGNC Symbol;Acc:HGNC:11159] SNRPD2
ENSG00000125971 dynein, light chain, roadblock-type 1 [Source:HGNC Symbol;Acc:HGNC:15468] DYNLRB1
ENSG00000125995 reactive oxygen species modulator 1 [Source:HGNC Symbol;Acc:HGNC:16185] ROMO1
ENSG00000126247 calpain, small subunit 1 [Source:HGNC Symbol;Acc:HGNC:1481] CAPNS1
ENSG00000126267 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) [Source:HGNC Symbol;Acc:HGNC:2280] COX6B1
ENSG00000126432 peroxiredoxin 5 [Source:HGNC Symbol;Acc:HGNC:9355] PRDX5
ENSG00000127022 calnexin [Source:HGNC Symbol;Acc:HGNC:1473] CANX
ENSG00000127184 cytochrome c oxidase subunit VIIc [Source:HGNC Symbol;Acc:HGNC:2292] COX7C
ENSG00000127922 split hand/foot malformation (ectrodactyly) type 1 [Source:HGNC Symbol;Acc:HGNC:10845] SHFM1
ENSG00000128272 activating transcription factor 4 [Source:HGNC Symbol;Acc:HGNC:786] ATF4
ENSG00000130770 ATPase inhibitory factor 1 [Source:HGNC Symbol;Acc:HGNC:871] ATPIF1
ENSG00000131143 cytochrome c oxidase subunit IV isoform 1 [Source:HGNC Symbol;Acc:HGNC:2265] COX4I1
ENSG00000132341 RAN, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:9846] RAN
ENSG00000132507 eukaryotic translation initiation factor 5A [Source:HGNC Symbol;Acc:HGNC:3300] EIF5A
ENSG00000133112 tumor protein, translationally-controlled 1 [Source:HGNC Symbol;Acc:HGNC:12022] TPT1
ENSG00000134333 lactate dehydrogenase A [Source:HGNC Symbol;Acc:HGNC:6535] LDHA
ENSG00000135390 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) [Source:HGNC Symbol;Acc:HGNC:842] ATP5G2
ENSG00000135404 CD63 molecule [Source:HGNC Symbol;Acc:HGNC:1692] CD63
ENSG00000135486 heterogeneous nuclear ribonucleoprotein A1 [Source:HGNC Symbol;Acc:HGNC:5031] HNRNPA1
ENSG00000135940 cytochrome c oxidase subunit Vb [Source:HGNC Symbol;Acc:HGNC:2269] COX5B
ENSG00000138668 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) [Source:HGNC Symbol;Acc:HGNC:5036] HNRNPD
ENSG00000139644 transmembrane BAX inhibitor motif containing 6 [Source:HGNC Symbol;Acc:HGNC:11723] TMBIM6
ENSG00000140264 small EDRK-rich factor 2 [Source:HGNC Symbol;Acc:HGNC:10757] SERF2
ENSG00000140319 signal recognition particle 14kDa (homologous Alu RNA binding protein) [Source:HGNC Symbol;Acc:HGNC:11299] SRP14
ENSG00000141522 Rho GDP dissociation inhibitor (GDI) alpha [Source:HGNC Symbol;Acc:HGNC:678] ARHGDIA
ENSG00000142089 interferon induced transmembrane protein 3 [Source:HGNC Symbol;Acc:HGNC:5414] IFITM3
ENSG00000142192 amyloid beta (A4) precursor protein [Source:HGNC Symbol;Acc:HGNC:620] APP
ENSG00000143761 ADP-ribosylation factor 1 [Source:HGNC Symbol;Acc:HGNC:652] ARF1
ENSG00000143933 calmodulin 2 (phosphorylase kinase, delta) [Source:HGNC Symbol;Acc:HGNC:1445] CALM2
ENSG00000145741 basic transcription factor 3 [Source:HGNC Symbol;Acc:HGNC:1125] BTF3
ENSG00000149806 Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed [Source:HGNC Symbol;Acc:HGNC:3597] FAU
ENSG00000149925 aldolase A, fructose-bisphosphate [Source:HGNC Symbol;Acc:HGNC:414] ALDOA
ENSG00000150991 ubiquitin C [Source:HGNC Symbol;Acc:HGNC:12468] UBC
ENSG00000152082 mitotic spindle organizing protein 2B [Source:HGNC Symbol;Acc:HGNC:25886] MZT2B
ENSG00000155368 diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) [Source:HGNC Symbol;Acc:HGNC:2690] DBI
ENSG00000156467 ubiquinol-cytochrome c reductase binding protein [Source:HGNC Symbol;Acc:HGNC:12582] UQCRB
ENSG00000156508 eukaryotic translation elongation factor 1 alpha 1 [Source:HGNC Symbol;Acc:HGNC:3189] EEF1A1
ENSG00000159199 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) [Source:HGNC Symbol;Acc:HGNC:841] ATP5G1
ENSG00000159335 parathymosin [Source:HGNC Symbol;Acc:HGNC:9629] PTMS
ENSG00000160014 calmodulin 3 (phosphorylase kinase, delta) [Source:HGNC Symbol;Acc:HGNC:1449] CALM3
ENSG00000161960 eukaryotic translation initiation factor 4A1 [Source:HGNC Symbol;Acc:HGNC:3282] EIF4A1
ENSG00000163041 H3 histone, family 3A [Source:HGNC Symbol;Acc:HGNC:4764] H3F3A
ENSG00000164405 ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa [Source:HGNC Symbol;Acc:HGNC:29594] UQCRQ
ENSG00000164919 cytochrome c oxidase subunit VIc [Source:HGNC Symbol;Acc:HGNC:2285] COX6C
ENSG00000165119 heterogeneous nuclear ribonucleoprotein K [Source:HGNC Symbol;Acc:HGNC:5044] HNRNPK
ENSG00000166165 creatine kinase, brain [Source:HGNC Symbol;Acc:HGNC:1991] CKB
ENSG00000166598 heat shock protein 90kDa beta (Grp94), member 1 [Source:HGNC Symbol;Acc:HGNC:12028] HSP90B1
ENSG00000166710 beta-2-microglobulin [Source:HGNC Symbol;Acc:HGNC:914] B2M
ENSG00000166794 peptidylprolyl isomerase B (cyclophilin B) [Source:HGNC Symbol;Acc:HGNC:9255] PPIB
ENSG00000167468 glutathione peroxidase 4 [Source:HGNC Symbol;Acc:HGNC:4556] GPX4
ENSG00000167552 tubulin, alpha 1a [Source:HGNC Symbol;Acc:HGNC:20766] TUBA1A
ENSG00000167553 tubulin, alpha 1c [Source:HGNC Symbol;Acc:HGNC:20768] TUBA1C
ENSG00000167658 eukaryotic translation elongation factor 2 [Source:HGNC Symbol;Acc:HGNC:3214] EEF2
ENSG00000167815 peroxiredoxin 2 [Source:HGNC Symbol;Acc:HGNC:9353] PRDX2
ENSG00000167996 ferritin, heavy polypeptide 1 [Source:HGNC Symbol;Acc:HGNC:3976] FTH1
ENSG00000168653 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme Q reductase) [Source:HGNC Symbol;Acc:HGNC:7712] NDUFS5
ENSG00000169020 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E [Source:HGNC Symbol;Acc:HGNC:846] ATP5I
ENSG00000169045 heterogeneous nuclear ribonucleoprotein H1 (H) [Source:HGNC Symbol;Acc:HGNC:5041] HNRNPH1
ENSG00000169100 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 [Source:HGNC Symbol;Acc:HGNC:10992] SLC25A6
ENSG00000169218 R-spondin 1 [Source:HGNC Symbol;Acc:HGNC:21679] RSPO1
ENSG00000170144 heterogeneous nuclear ribonucleoprotein A3 [Source:HGNC Symbol;Acc:HGNC:24941] HNRNPA3
ENSG00000170296 GABA(A) receptor-associated protein [Source:HGNC Symbol;Acc:HGNC:4067] GABARAP
ENSG00000170315 ubiquitin B [Source:HGNC Symbol;Acc:HGNC:12463] UBB
ENSG00000170906 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa [Source:HGNC Symbol;Acc:HGNC:7686] NDUFA3
ENSG00000171530 tubulin folding cofactor A [Source:HGNC Symbol;Acc:HGNC:11579] TBCA
ENSG00000172270 basigin (Ok blood group) [Source:HGNC Symbol;Acc:HGNC:1116] BSG
ENSG00000172354 guanine nucleotide binding protein (G protein), beta polypeptide 2 [Source:HGNC Symbol;Acc:HGNC:4398] GNB2
ENSG00000172757 cofilin 1 (non-muscle) [Source:HGNC Symbol;Acc:HGNC:1874] CFL1
ENSG00000173113 tRNA methyltransferase 11-2 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:26940] TRMT112
ENSG00000173660 ubiquinol-cytochrome c reductase hinge protein [Source:HGNC Symbol;Acc:HGNC:12590] UQCRH
ENSG00000173915 up-regulated during skeletal muscle growth 5 homolog (mouse) [Source:HGNC Symbol;Acc:HGNC:30889] USMG5
ENSG00000176340 cytochrome c oxidase subunit VIIIA (ubiquitous) [Source:HGNC Symbol;Acc:HGNC:2294] COX8A
ENSG00000179010 Morf4 family associated protein 1 [Source:HGNC Symbol;Acc:HGNC:24549] MRFAP1
ENSG00000179218 calreticulin [Source:HGNC Symbol;Acc:HGNC:1455] CALR
ENSG00000180879 signal sequence receptor, delta [Source:HGNC Symbol;Acc:HGNC:11326] SSR4
ENSG00000181163 nucleophosmin (nucleolar phosphoprotein B23, numatrin) [Source:HGNC Symbol;Acc:HGNC:7910] NPM1
ENSG00000184009 actin, gamma 1 [Source:HGNC Symbol;Acc:HGNC:144] ACTG1
ENSG00000185201 interferon induced transmembrane protein 2 [Source:HGNC Symbol;Acc:HGNC:5413] IFITM2
ENSG00000185624 prolyl 4-hydroxylase, beta polypeptide [Source:HGNC Symbol;Acc:HGNC:8548] P4HB
ENSG00000185787 mortality factor 4 like 1 [Source:HGNC Symbol;Acc:HGNC:16989] MORF4L1
ENSG00000185883 ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c [Source:HGNC Symbol;Acc:HGNC:855] ATP6V0C
ENSG00000186010 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 [Source:HGNC Symbol;Acc:HGNC:17194] NDUFA13
ENSG00000187514 prothymosin, alpha [Source:HGNC Symbol;Acc:HGNC:9623] PTMA
ENSG00000189403 high mobility group box 1 [Source:HGNC Symbol;Acc:HGNC:4983] HMGB1
ENSG00000196230 tubulin, beta class I [Source:HGNC Symbol;Acc:HGNC:20778] TUBB
ENSG00000196262 peptidylprolyl isomerase A (cyclophilin A) [Source:HGNC Symbol;Acc:HGNC:9253] PPIA
ENSG00000196531 nascent polypeptide-associated complex alpha subunit [Source:HGNC Symbol;Acc:HGNC:7629] NACA
ENSG00000196683 translocase of outer mitochondrial membrane 7 homolog (yeast) [Source:HGNC Symbol;Acc:HGNC:21648] TOMM7
ENSG00000197111 poly(rC) binding protein 2 [Source:HGNC Symbol;Acc:HGNC:8648] PCBP2
ENSG00000197746 prosaposin [Source:HGNC Symbol;Acc:HGNC:9498] PSAP
ENSG00000198258 ubiquitin-like 5 [Source:HGNC Symbol;Acc:HGNC:13736] UBL5
ENSG00000198830 high mobility group nucleosomal binding domain 2 [Source:HGNC Symbol;Acc:HGNC:4986] HMGN2
ENSG00000204525 major histocompatibility complex, class I, C [Source:HGNC Symbol;Acc:HGNC:4933] HLA-C
ENSG00000204628 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 [Source:HGNC Symbol;Acc:HGNC:4399] GNB2L1
ENSG00000205352 proline rich 13 [Source:HGNC Symbol;Acc:HGNC:24528] PRR13
ENSG00000205542 thymosin beta 4, X-linked [Source:HGNC Symbol;Acc:HGNC:11881] TMSB4X
ENSG00000206503 major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931] HLA-A
ENSG00000219200 ribonuclease, RNase K [Source:HGNC Symbol;Acc:HGNC:33911] RNASEK
ENSG00000228474 oligosaccharyltransferase 4 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:32483] OST4
ENSG00000232112 translation machinery associated 7 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:26932] TMA7
ENSG00000234745 major histocompatibility complex, class I, B [Source:HGNC Symbol;Acc:HGNC:4932] HLA-B
ENSG00000241468 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2 [Source:HGNC Symbol;Acc:HGNC:848] ATP5J2
ENSG00000254772 eukaryotic translation elongation factor 1 gamma [Source:HGNC Symbol;Acc:HGNC:3213] EEF1G
ENSG00000255823 MT-RNR2-like 8 [Source:HGNC Symbol;Acc:HGNC:37165] MTRNR2L8
ENSG00000256045 MT-RNR2-like 10 [Source:HGNC Symbol;Acc:HGNC:37167] MTRNR2L10
ENSG00000256222 MT-RNR2-like 3 [Source:HGNC Symbol;Acc:HGNC:37157] MTRNR2L3
ENSG00000256618 MT-RNR2-like 1 [Source:HGNC Symbol;Acc:HGNC:37155] MTRNR2L1
Ensembl Gene ID Description MGI symbol
ENSMUSG00000000682 CD52 antigen [Source:MGI Symbol;Acc:MGI:1346088] Cd52
ENSMUSG00000001666 D-dopachrome tautomerase [Source:MGI Symbol;Acc:MGI:1298381] Ddt
ENSMUSG00000011752 phosphoglycerate mutase 1 [Source:MGI Symbol;Acc:MGI:97552] Pgam1
ENSMUSG00000015656 heat shock protein 8 [Source:MGI Symbol;Acc:MGI:105384] Hspa8
ENSMUSG00000016319
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 [Source:MGI 
Symbol;Acc:MGI:1353496] Slc25a5
ENSMUSG00000017778 cytochrome c oxidase subunit VIIc [Source:MGI Symbol;Acc:MGI:103226] Cox7c
ENSMUSG00000018293 profilin 1 [Source:MGI Symbol;Acc:MGI:97549] Pfn1
ENSMUSG00000019505 ubiquitin B [Source:MGI Symbol;Acc:MGI:98888] Ubb
ENSMUSG00000020018 small nuclear ribonucleoprotein polypeptide F [Source:MGI Symbol;Acc:MGI:1917128] Snrpf
ENSMUSG00000020163 ubiquinol-cytochrome c reductase, complex III subunit XI [Source:MGI Symbol;Acc:MGI:1913844] Uqcr11
ENSMUSG00000020219 translocase of inner mitochondrial membrane 13 [Source:MGI Symbol;Acc:MGI:1353432] Timm13
ENSMUSG00000020372
guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 [Source:MGI 
Symbol;Acc:MGI:101849] Gnb2l1
ENSMUSG00000020738 SMT3 suppressor of mif two 3 homolog 2 (yeast) [Source:MGI Symbol;Acc:MGI:2158813] Sumo2
ENSMUSG00000020857 NME/NM23 nucleoside diphosphate kinase 2 [Source:MGI Symbol;Acc:MGI:97356] Nme2
Mouse HE-NRGs
ENSMUSG00000021131 enhancer of rudimentary homolog (Drosophila) [Source:MGI Symbol;Acc:MGI:108089] Erh
ENSMUSG00000021520 ubiquinol-cytochrome c reductase binding protein [Source:MGI Symbol;Acc:MGI:1914780] Uqcrb
ENSMUSG00000021660 basic transcription factor 3 [Source:MGI Symbol;Acc:MGI:1202875] Btf3
ENSMUSG00000022982 superoxide dismutase 1, soluble [Source:MGI Symbol;Acc:MGI:98351] Sod1
ENSMUSG00000023004 tubulin, alpha 1B [Source:MGI Symbol;Acc:MGI:107804] Tuba1b
ENSMUSG00000024653 secretoglobin, family 1A, member 1 (uteroglobin) [Source:MGI Symbol;Acc:MGI:98919] Scgb1a1
ENSMUSG00000024661 ferritin heavy chain 1 [Source:MGI Symbol;Acc:MGI:95588] Fth1
ENSMUSG00000026162 nonhomologous end-joining factor 1 [Source:MGI Symbol;Acc:MGI:1922820] Nhej1
ENSMUSG00000026238 prothymosin alpha [Source:MGI Symbol;Acc:MGI:97803] Ptma
ENSMUSG00000027907 S100 calcium binding protein A11 (calgizzarin) [Source:MGI Symbol;Acc:MGI:1338798] S100a11
ENSMUSG00000027944 HCLS1 associated X-1 [Source:MGI Symbol;Acc:MGI:1346319] Hax1
ENSMUSG00000028333 acidic (leucine-rich) nuclear phosphoprotein 32 family, member B [Source:MGI Symbol;Acc:MGI:1914878] Anp32b
ENSMUSG00000028367 thioredoxin 1 [Source:MGI Symbol;Acc:MGI:98874] Txn1
ENSMUSG00000028773 fatty acid binding protein 3, muscle and heart [Source:MGI Symbol;Acc:MGI:95476] Fabp3
ENSMUSG00000029075 tumor necrosis factor receptor superfamily, member 4 [Source:MGI Symbol;Acc:MGI:104512] Tnfrsf4
ENSMUSG00000029368 albumin [Source:MGI Symbol;Acc:MGI:87991] Alb
ENSMUSG00000029580 actin, beta [Source:MGI Symbol;Acc:MGI:87904] Actb
ENSMUSG00000030695 aldolase A, fructose-bisphosphate [Source:MGI Symbol;Acc:MGI:87994] Aldoa
ENSMUSG00000031146 proteolipid protein 2 [Source:MGI Symbol;Acc:MGI:1298382] Plp2
ENSMUSG00000031231 cytochrome c oxidase subunit VIIb [Source:MGI Symbol;Acc:MGI:1913392] Cox7b
ENSMUSG00000031765 metallothionein 1 [Source:MGI Symbol;Acc:MGI:97171] Mt1
ENSMUSG00000032294 pyruvate kinase, muscle [Source:MGI Symbol;Acc:MGI:97591] Pkm
ENSMUSG00000033307 macrophage migration inhibitory factor [Source:MGI Symbol;Acc:MGI:96982] Mif
ENSMUSG00000034566
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit D [Source:MGI 
Symbol;Acc:MGI:1918929] Atp5h
ENSMUSG00000035215 LSM7 homolog, U6 small nuclear RNA associated (S. cerevisiae) [Source:MGI Symbol;Acc:MGI:1913344] Lsm7
ENSMUSG00000035242 ornithine decarboxylase antizyme 1 [Source:MGI Symbol;Acc:MGI:109433] Oaz1
ENSMUSG00000036752 tubulin, beta 4B class IVB [Source:MGI Symbol;Acc:MGI:1915472] Tubb4b
ENSMUSG00000036835 presenilin enhancer 2 homolog (C. elegans) [Source:MGI Symbol;Acc:MGI:1913590] Psenen
ENSMUSG00000038274
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived) [Source:MGI 
Symbol;Acc:MGI:102547] Fau
ENSMUSG00000038717
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G [Source:MGI 
Symbol;Acc:MGI:1351597] Atp5l
ENSMUSG00000041697 cytochrome c oxidase subunit VIa polypeptide 1 [Source:MGI Symbol;Acc:MGI:103099] Cox6a1
ENSMUSG00000049775 thymosin, beta 4, X chromosome [Source:MGI Symbol;Acc:MGI:99510] Tmsb4x
ENSMUSG00000050708 ferritin light chain 1 [Source:MGI Symbol;Acc:MGI:95589] Ftl1
ENSMUSG00000052305 hemoglobin, beta adult s chain [Source:MGI Symbol;Acc:MGI:5474852] Hbb-bs
ENSMUSG00000053317 Sec61 beta subunit [Source:MGI Symbol;Acc:MGI:1913462] Sec61b
ENSMUSG00000054106 trypsin 4 [Source:MGI Symbol;Acc:MGI:102757] Try4
ENSMUSG00000055302 Morf4 family associated protein 1 [Source:MGI Symbol;Acc:MGI:1914818] Mrfap1
ENSMUSG00000057113 nucleophosmin 1 [Source:MGI Symbol;Acc:MGI:106184] Npm1
ENSMUSG00000057506 biogenesis of lysosomal organelles complex-1, subunit 2 [Source:MGI Symbol;Acc:MGI:1920939] Bloc1s2
ENSMUSG00000058126 tropomyosin 3, related sequence 7 [Source:MGI Symbol;Acc:MGI:99705] Tpm3-rs7
ENSMUSG00000059040 enolase 1B, retrotransposed [Source:MGI Symbol;Acc:MGI:3648653] Eno1b
ENSMUSG00000060591 interferon induced transmembrane protein 2 [Source:MGI Symbol;Acc:MGI:1933382] Ifitm2
ENSMUSG00000060802 beta-2 microglobulin [Source:MGI Symbol;Acc:MGI:88127] B2m
ENSMUSG00000060803 glutathione S-transferase, pi 1 [Source:MGI Symbol;Acc:MGI:95865] Gstp1
ENSMUSG00000061315 nascent polypeptide-associated complex alpha polypeptide [Source:MGI Symbol;Acc:MGI:106095] Naca
ENSMUSG00000061482 histone cluster 1, H4d [Source:MGI Symbol;Acc:MGI:2448423] Hist1h4d
ENSMUSG00000061518 cytochrome c oxidase subunit Vb [Source:MGI Symbol;Acc:MGI:88475] Cox5b
ENSMUSG00000062070 phosphoglycerate kinase 1 [Source:MGI Symbol;Acc:MGI:97555] Pgk1
ENSMUSG00000062248 CDC28 protein kinase regulatory subunit 2 [Source:MGI Symbol;Acc:MGI:1913447] Cks2
ENSMUSG00000062683
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C2 (subunit 9) [Source:MGI 
Symbol;Acc:MGI:1915192] Atp5g2
ENSMUSG00000062825 actin, gamma, cytoplasmic 1 [Source:MGI Symbol;Acc:MGI:87906] Actg1
ENSMUSG00000062867 inosine 5'-phosphate dehydrogenase 2 [Source:MGI Symbol;Acc:MGI:109367] Impdh2
ENSMUSG00000063229 lactate dehydrogenase A [Source:MGI Symbol;Acc:MGI:96759] Ldha
ENSMUSG00000063524 enolase 1, alpha non-neuron [Source:MGI Symbol;Acc:MGI:95393] Eno1
ENSMUSG00000064213 defensin, alpha, 24 [Source:MGI Symbol;Acc:MGI:3630383] Defa24
ENSMUSG00000064341 mitochondrially encoded NADH dehydrogenase 1 [Source:MGI Symbol;Acc:MGI:101787] mt-Nd1
ENSMUSG00000064345 mitochondrially encoded NADH dehydrogenase 2 [Source:MGI Symbol;Acc:MGI:102500] mt-Nd2
ENSMUSG00000064351 mitochondrially encoded cytochrome c oxidase I [Source:MGI Symbol;Acc:MGI:102504] mt-Co1
ENSMUSG00000064356 mitochondrially encoded ATP synthase 8 [Source:MGI Symbol;Acc:MGI:99926] mt-Atp8
ENSMUSG00000064357 mitochondrially encoded ATP synthase 6 [Source:MGI Symbol;Acc:MGI:99927] mt-Atp6
ENSMUSG00000064360 mitochondrially encoded NADH dehydrogenase 3 [Source:MGI Symbol;Acc:MGI:102499] mt-Nd3
ENSMUSG00000064363 mitochondrially encoded NADH dehydrogenase 4 [Source:MGI Symbol;Acc:MGI:102498] mt-Nd4
ENSMUSG00000064367 mitochondrially encoded NADH dehydrogenase 5 [Source:MGI Symbol;Acc:MGI:102496] mt-Nd5
ENSMUSG00000064368 mitochondrially encoded NADH dehydrogenase 6 [Source:MGI Symbol;Acc:MGI:102495] mt-Nd6
ENSMUSG00000064370 mitochondrially encoded cytochrome b [Source:MGI Symbol;Acc:MGI:102501] mt-Cytb
ENSMUSG00000069117 predicted gene 10260 [Source:MGI Symbol;Acc:MGI:3642298] Gm10260
ENSMUSG00000069744 proteasome (prosome, macropain) subunit, beta type 3 [Source:MGI Symbol;Acc:MGI:1347014] Psmb3
ENSMUSG00000069919 hemoglobin alpha, adult chain 1 [Source:MGI Symbol;Acc:MGI:96015] Hba-a1
ENSMUSG00000070493 coiled-coil-helix-coiled-coil-helix domain containing 2 [Source:MGI Symbol;Acc:MGI:1261428] Chchd2
ENSMUSG00000071528 upregulated during skeletal muscle growth 5 [Source:MGI Symbol;Acc:MGI:1891435] Usmg5
ENSMUSG00000071866 peptidylprolyl isomerase A [Source:MGI Symbol;Acc:MGI:97749] Ppia
ENSMUSG00000073940 hemoglobin, beta adult t chain [Source:MGI Symbol;Acc:MGI:5474850] Hbb-bt
ENSMUSG00000074516 predicted gene 10709 [Source:MGI Symbol;Acc:MGI:3642754] Gm10709
ENSMUSG00000074695 interleukin 22 [Source:MGI Symbol;Acc:MGI:1355307] Il22
ENSMUSG00000075014 predicted gene 10800 [Source:MGI Symbol;Acc:MGI:3641657] Gm10800
ENSMUSG00000075602 lymphocyte antigen 6 complex, locus A [Source:MGI Symbol;Acc:MGI:107527] Ly6a
ENSMUSG00000078193 predicted gene 2000 [Source:MGI Symbol;Acc:MGI:3780170] Gm2000
ENSMUSG00000078427 SAP domain containing ribonucleoprotein [Source:MGI Symbol;Acc:MGI:1913368] Sarnp
ENSMUSG00000078672 major urinary protein 20 [Source:MGI Symbol;Acc:MGI:3651981] Mup20
ENSMUSG00000078974 SEC61, gamma subunit [Source:MGI Symbol;Acc:MGI:1202066] Sec61g
ENSMUSG00000079010 predicted gene 11032 [Source:MGI Symbol;Acc:MGI:3779255] Gm11032
ENSMUSG00000079018 lymphocyte antigen 6 complex, locus C1 [Source:MGI Symbol;Acc:MGI:96882] Ly6c1
ENSMUSG00000079019 insulin-like 3 [Source:MGI Symbol;Acc:MGI:108427] Insl3
ENSMUSG00000079523 thymosin, beta 10 [Source:MGI Symbol;Acc:MGI:109146] Tmsb10
ENSMUSG00000079600 predicted gene, 17604 [Source:MGI Symbol;Acc:MGI:4937238] Gm17604
ENSMUSG00000079740 predicted gene 11172 [Source:MGI Symbol;Acc:MGI:3779427] Gm11172
ENSMUSG00000090592 predicted gene, 17571 [Source:MGI Symbol;Acc:MGI:4937205] Gm17571
ENSMUSG00000090625 predicted gene, 20721 [Source:MGI Symbol;Acc:MGI:5313030] Gm20721
ENSMUSG00000090841 myosin, light polypeptide 6, alkali, smooth muscle and non-muscle [Source:MGI Symbol;Acc:MGI:109318] Myl6
ENSMUSG00000090889 predicted gene, 17428 [Source:MGI Symbol;Acc:MGI:4937062] Gm17428
ENSMUSG00000091159 predicted gene, 17545 [Source:MGI Symbol;Acc:MGI:4937179] Gm17545




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































K562 GM12878 h1hESC HeLaS3 HepG2 A549
KAT2A NaN 4.131	2e-06 NaN 3.333	3.7e-06 NaN NaN
ZZZ3 NaN 4.394	2e-06 NaN NaN NaN NaN
RCOR1 NaN 2.684	0.0064 NaN NaN NaN NaN
BRCA1 NaN 2.095	0.00091 NaN NaN NaN NaN
SIX5 0.696	0.0085 0.579	0.0013 NaN NaN NaN 0.809	0.0033
HDAC6 1.472	0.0077 NaN NaN NaN NaN NaN
RCOR1 NaN 1.394	0.0067 NaN NaN NaN NaN
TAF7 0.824	4.9e-06 NaN NaN NaN NaN NaN
MYC NaN 0.536	0.0012 NaN NaN 0.259	0.0093 NaN
GTF2B 0.667	0.00029 NaN NaN NaN NaN NaN
CHD1 NaN NaN 0.394	0.0096 NaN NaN NaN
GTF2F1 0.348	0.004 NaN NaN NaN NaN NaN
POL2 NaN NaN 0.293	0.0022 NaN NaN NaN
SP1 NaN -0.442	0.0094 NaN NaN NaN NaN
ELF1 NaN -0.538	0.00091 NaN NaN NaN NaN
RUNX3 NaN -0.590	0.0031 NaN NaN NaN NaN
EGR1 NaN -0.715	0.00091 NaN NaN NaN NaN
CREB1 NaN NaN NaN NaN NaN -0.789	0.0033
BACH1 NaN NaN -0.907	0.0096 NaN NaN NaN
EBF1 NaN -0.932	0.0007 NaN NaN NaN NaN
TBP -0.943	3.9e-05 NaN NaN NaN NaN NaN
USF2 NaN -0.958	0.0055 NaN NaN NaN NaN
TFAP2C NaN NaN NaN -1.097	6.2e-05 NaN NaN
TFAP2A NaN NaN NaN -1.102	6.1e-05 NaN NaN
AP2ALPHA NaN NaN NaN -1.102	6.1e-05 NaN NaN
TAF1 NaN -0.613	0.00018 -0.493	0.0022 NaN NaN NaN
AP2GAMMA NaN NaN NaN -1.145	3.5e-05 NaN NaN
HAE2F1 NaN NaN NaN -1.198	2.2e-05 NaN NaN
E2F1 NaN NaN NaN -1.215	0.00018 NaN NaN
MAZ NaN -0.795	5e-05 NaN -0.615	0.0026 NaN NaN
P300 NaN NaN NaN -1.444	0.0069 NaN NaN
EP300 NaN NaN NaN -1.444	0.0069 NaN NaN
UBTF -1.789	4.9e-06 NaN NaN NaN NaN NaN
NRF1 NaN -0.609	0.008 NaN -1.254	0.0032 NaN NaN
MAFK NaN NaN -2.701	0.0022 NaN NaN NaN
NFYA NaN -1.913	0.00064 NaN -0.871	0.004 NaN NaN
ZBTB7 -1.054	0.0002 NaN NaN NaN -1.869	2.1e-05 NaN
NFE2 -3.145	0.0013 NaN NaN NaN NaN NaN
NFYB -0.828	0.0047 -0.756	0.0086 NaN -1.620	2.1e-05 NaN NaN
FOS -1.071	0.0023 -1.913	5e-05 NaN -2.360	0.00024 NaN NaN






K562 human SIN3 IRF1 HDAC8 NFYB MYC GTF2F1 TAF1 ETS1 EJUNB JUNB CTCFC RFX5 CEBPB SETDB1 RDBP MAFF CJUN NRF1 CHD1 NELFE
MEL mouse TAL1 ZKSCAN1MYC CTCF USF2 RCOR1 NELFE RAD21 CHD2 EP300 ZC3H11ARpII215KAT2A GATA1 GABPA E2F4 ETS1 HCFC1 MYB SIN3A
GM12898 human TBLR1NFYB RAD21 NRSF REST MEF2 USF2 KAT2AJUND NFIC BRCA1 STAT3ETS1 RCOR1 NFYA CHD1 MTA3 POL2 PML TAF1
CH12.LX mouse HCFC1 GABPAEP300 E2F4 CTCF KAT2A TBP ZKSCAN1CHD2 RpII215 RCOR1 USF2 JUN POLR2AphosphoS2MAZ ETS1 PAX5 NELFE ZNF384 UBTF
Table S12. TRs selected for most accurate prediction of transcript 
levels. Sets of 20 TRs identified by LARS are shown for human and mouse 
cell lines. 
